EMA Re-Examines Decisions On Prestige’s Trastuzumab And Synchron Studies
CHMP Rejection Of Herceptin Biosimilar And Suspension Of Generics To Be Reviewed
• By David Wallace
The EMA will review a pair of CHMP decisions following re-examination requests 
